Objective menu
01
Choose your objective
Start with the GTM outcome: trust data, grow pipeline, find missing accounts, improve segmentation, clean routing, or size growth.
Stridefor
Company intelligence that finds funded biotech companies before vendor need is obvious
How it works
From market definition to live GTM motion that finds funded biotech companies before vendor need is obvious
ICP model
biotech companies by stage, pipeline, funding, and R&D in...
Lifecycle stage
Pipeline focus
Funding profile
Account list
scoredBest-fit accounts94%
Expansion list81%
Review queue67%
02
Define ICP and build account lists
Describe your ICP in plain language. Stride turns it into a benchmarked account model using fit rules, exclusions, entity structure, and Lifecycle stage, Pipeline focus, Funding profile, and R&D intensity.
CRM sync
03
Power GTM motions within your existing tools
Push enriched accounts into Salesforce or HubSpot for ABM, territory mapping, TAM sizing, outbound, events, email, and in-person motions.
Workflow Context
Generic firmographics miss the buying context that changes fit
Useful targeting for biotech companies by stage, pipeline, funding, and R&D intensity depends on Lifecycle stage, Pipeline focus, Funding profile, and R&D intensity. Stride turns those signals into fields your team can review and deploy.
Workflow map
Biotechnology
Signals
Lifecycle stage01
Pipeline focus02
Funding profile03
R&D intensity04
Workflow outputs
Separate discovery, preclinical, clinical, and commercial-stage companies.
Prioritise accounts where funding and pipeline activity indicate near-term vendor need.
Route messaging by therapeutic area, modality, and development milestone.
Enrich
Score
Deploy
- Use Lifecycle stage for segmentation, scoring, and routing.
- Use Pipeline focus for segmentation, scoring, and routing.
- Use Funding profile for segmentation, scoring, and routing.
- Use R&D intensity for segmentation, scoring, and routing.
Sector Signals
Model the signals that decide which accounts are worth working
Footprint layers sector-specific signals onto core company data so account selection reflects how the market actually operates.
Signal model
Target model
Biotechnology
biotech companies by stage, pipeline, funding, and R&D intensity
01Lifecycle stageFielded for fit, routing, and evidence
02Pipeline focusFielded for fit, routing, and evidence
03Funding profileFielded for fit, routing, and evidence
04R&D intensityFielded for fit, routing, and evidence
- Separate discovery, preclinical, clinical, and commercial-stage companies.
- Prioritise accounts where funding and pipeline activity indicate near-term vendor need.
- Route messaging by therapeutic area, modality, and development milestone.
- Detect companies moving from science-led research into operational scale.
Workflow Prioritisation
Prioritise accounts around clinical stage, therapeutic focus, financing runway, and research intensity
Opportunity Sizing turns the enriched company layer into account tiers, whitespace lists, and targeting rules your team can use.
Benchmark view
- Add lifecycle, modality, funding, and trial-stage context to account records.
- Create segments for lab tooling, CRO, CDMO, data, and commercial readiness motions.
- Surface whitespace accounts missed by broad healthcare or pharma categories.
- Keep sales lists updated as funding, trial, and hiring signals change.
Deployable Output
Deploy account intelligence into live GTM workflows
Stride sends reviewed recommendations, CRM-ready fields, and scored lists into the systems your team already uses.
Deployment flow
CRM deployment
Account records into the systems your team already uses
Ready fields
Lifecycle stageready
Pipeline focusready
Funding profileready
R&D intensityready
Map fields
Review rules
Sync records
CRM fields
No overwrite risk
Activation ready
- Recommend the accounts most likely to match your motion.
- Show evidence and confidence for each suggestion.
- Route outputs into CRM, ABM, outbound, planning, and partner workflows.
- Control rollout with approvals, overwrite rules, and deployment caps.